Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Eukaryotic translation elongation factor 1 beta 2 pseudogene 5 (EEF1B2P5) is a processed pseudogene in the human genome, classified among several (at least eight) EEF1B2 pseudogenes, believed to have arisen via retrotransposition events. Unlike its parent gene EEF1B2, which is a component of the eEF1H complex involved in protein elongation during translation, EEF1B2P5 does not encode a functional protein and has not been implicated in biological processes, disease mechanisms, or therapeutic intervention. No experimental evidence links EEF1B2P5 to pathological states or molecular function, and it is not considered a therapeutic target[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Eukaryotic translation elongation factor 1 beta 2 pseudogene 5 (EEF1B2P5).